XHEL
OPTOMED
Market cap41mUSD
Jul 09, Last price
1.70EUR
1D
-1.16%
1Q
-26.72%
IPO
-72.58%
Name
Optomed Oyj
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Optomed Oyj, established in 2004 and headquartered in Oulu, Finland, is a medical technology company specializing in the development, production, and sale of portable devices for retinal examination and advanced screening software. The company operates globally, with a presence in Finland and China, structured into dedicated Devices and Software segments. Its Device division focuses on fundus cameras, serving a broad spectrum of medical specialists, including ophthalmologists, pediatricians, endocrinologists, neurologists, and general practitioners. These camera products are marketed under Optomed's own brand names such as Optomed Smartscope Pro, Aurora, Polaris, and Halo, and are also provided as OEM products under labels including Pictor Plus, Pictor Prestige, Visuscout 100, Fundus Module 300, and Signal. The Software segment offers a comprehensive suite of solutions. For eye health, this includes Avenue Eye Screen for managing the workflow of eye disease screening and monitoring (like diabetic retinopathy), Avenue Archive for healthcare data storage and transmission, Avenue Telemedicine for remote image analysis, Avenue AI for automated diabetic retinopathy screening, and Avenue Sync for seamless integration of fundus cameras with hospital systems. Beyond eye care, Optomed provides Avenue Cancer Screen for managing breast, cervical, and colorectal cancer screenings; Optomed RIS for optimizing diagnostic processes in healthcare imaging units; Sectra PACS, a scalable system for high-volume healthcare providers; Optomed Service Portal for supporting imaging service operations; Facad for visible light imaging and cephalometric tracing; and Sectra PACS Pathology, a digital solution for the distribution and diagnosis of scanned glass slides. Furthermore, Optomed extends professional IT consulting services to government bodies. The company's products and solutions are distributed through OEMs, authorized distributors, and its direct sales channels. Its primary clientele includes hospitals, specialized eye clinics, and both independent and chain optician stores.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||